» Articles » PMID: 21715541

Soluble FMS-like Tyrosine Kinase-1 (sFlt-1) and Serum Placental Growth Factor (PlGF) As Biomarkers for Ectopic Pregnancy and Missed Abortion

Overview
Specialty Endocrinology
Date 2011 Jul 1
PMID 21715541
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Diagnosis of early pregnancy failure is hampered by the lack of reliable serological markers.

Objective: We assessed whether a single serum measurement of placental growth factor (PlGF) and the soluble Flt-1 (sFlt-1) receptor of vascular endothelial growth factor at 6-8 wk gestation could differentiate failed pregnancies, whether ectopic pregnancies (EP) or missed abortions (MA), from healthy intrauterine pregnancies (IUP).

Design And Setting: We conducted a prospective clinical study at a tertiary university hospital between January 2009 and February 2011.

Patients: A total of 78 consecutive patients (38 EP, 40 MA) with failed early pregnancy and 50 IUP (control group) participated in the study.

Intervention(s): Determination of serum PlGF and sFlt-1 has been carried out by ELISA. Gene expression of PlGF and Flt-1 in trophoblasts was performed by RT-PCR.

Main Outcome Measure(s): We investigated whether a single, combined serum measurement of the above markers could contribute to the differential diagnosis.

Results: PlGF and sFlt-1 concentration was lower in both EP (mean, 14.60 ± 3.42/178.16 ± 76.03 pg/ml) and MA (mean, 16.25 ± 4.73/399.42 ± 337.54 pg/ml) compared to IUP (mean, 21.64 ± 5.68/1390.32 ± 655.37 pg/ml). sFlt-1 (P = 0.033) and sFlt-1/PlGF ratio (P = 0.029) but not PlGF had the ability to discriminate MA from EP. Compared to women with viable IUP, mRNA gene expression levels of PlGF and Flt-1 were considerably lower in women with MA and in women with EP.

Conclusions: Combined measurement of sFlt-1 and PlGF levels can differentiate normal from failed pregnancies, whereas sFlt-1 as well as sFlt-1/PlGF ratio can also discriminate EP from MA. PlGF and Flt-1 gene expression in trophoblasts from women with EP and MA appears impaired.

Citing Articles

Biochemical markers for prediction of the first half pregnancy losses: a review.

Kuspanova M, Gaiday A, Dzhardemaliyeva N, Tuganbayev M, Gorobeiko M, Dinets A Rev Bras Ginecol Obstet. 2024; 46.

PMID: 39380582 PMC: 11460427. DOI: 10.61622/rbgo/2024rbgo72.


Are Altered Expression of Vascular Endothelial Growth Factor and Placental Growth Factor Associated with Placental Angiogenesis in Recurrent Pregnancy Loss?.

Sultana S, Renjini Devi M, Rathod M, Reddy P, Ananthapur V Indian J Clin Biochem. 2024; 39(3):387-391.

PMID: 39005877 PMC: 11239627. DOI: 10.1007/s12291-023-01117-4.


Nanomedicines for Improved Management of Ectopic Pregnancy: A Narrative Review.

Moses A, Korzun T, Mamnoon B, Baldwin M, Myatt L, Taratula O Small. 2023; 20(41):e2301873.

PMID: 37471169 PMC: 10837845. DOI: 10.1002/smll.202301873.


Literature Review: The sFlt1/PlGF Ratio and Pregestational Maternal Comorbidities: New Risk Factors to Predict Pre-Eclampsia.

Karpova N, Dmitrenko O, Budykina T Int J Mol Sci. 2023; 24(7).

PMID: 37047717 PMC: 10095124. DOI: 10.3390/ijms24076744.


Validation of a multiple marker test for early pregnancy outcome prediction.

Bollig K, Senapati S, Sammel M, Takacs P, Robins J, Haisenleder D J Assist Reprod Genet. 2023; 40(4):837-844.

PMID: 36708430 PMC: 10224881. DOI: 10.1007/s10815-023-02719-w.